Evidence map›Paper›PMID 28551176›Full record

ArticleEuropean journal of medicinal chemistry2017

A unique mid-sequence linker used to multimerize the lipid-phosphatidylserine (PS) binding peptide-peptoid hybrid PPS1.

Satya Prakash Shukla, Joseph C Manarang, D Gomika Udugamasooriya

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Satya Prakash ShuklaDepartment of Pharmacological & Pharmaceutical Sciences, University of Houston, 3455 Cullen Blvd., Houston, TX 77204-5037, USA.
Joseph C ManarangDepartment of Pharmacological & Pharmaceutical Sciences, University of Houston, 3455 Cullen Blvd., Houston, TX 77204-5037, USA.
D Gomika UdugamasooriyaDepartment of Pharmacological & Pharmaceutical Sciences, University of Houston, 3455 Cullen Blvd., Houston, TX 77204-5037, USA; Department of Cancer Systems Imaging, MD Anderson Cancer Center, 1881 East Road, Houston, TX 77030-4009, USA. Electronic address: gomika@uh.edu.
University of Houston · USThe University of Texas MD Anderson Cancer Center · US

Funding

Phosphatidylserine Targeted Tumor Cell Lytic PeptoidsR01CA175779 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI UDUGAMASOORIYA, DAMITH GOMIKA · 2013 to 2017
$1.5M
NCI NIH HHS R01 CA175779
6 · The paper itself

Abstract

Ligand multimerizations enhance the binding affinity towards cell surface biomarkers through their avidity effects. Typical linkers connect individual monomeric ligand moieties from one end (e.g., C- or N-terminus of a peptide) and exclusively target protein receptors. The lipid phosphatidylserine (PS) is normally present on the cytoplasmic side of the eukaryotic cell membrane, but in tumors and tumor endothelial cells, this negatively charged PS flips to the outer layer. We recently reported a PS binding peptide-peptoid hybrid (PPS1) that has distinct positively charged and hydrophobic residue-containing regions. The PPS1 monomer is inactive, and upon C-terminal dimerization (PPS1D1), it triggers cytotoxicity. In the current study, a unique series of PPS1 multimeric derivatives were synthesized by switching the linker from the C-terminus to an internal position. The unimportant fourth residue (N-lys) from the C-terminus was utilized to build the linker. The synthesis strategy was developed employing variations of (I) the linker size, (II) the number of positively charged residues, and (III) the number of hydrophobic regions. Cytotoxicity of these new derivatives on HCC4017 lung cancer cells showed that a minimum of two hydrophobic regions was important to retain the activity and that the shortest linker length was optimal for activity.

Indexed as

Binding SitesCell Line, TumorCell SurvivalDose-Response Relationship, DrugHumansLipidsMolecular StructurePeptidesPhosphatidylserinesStructure-Activity RelationshipLipidsPeptidesPhosphatidylserinesMultimersPeptoidsSequence modifications

Identifiers

PMID28551176
PMCPMC5555622
OpenAlexW2614369299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.